Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Scott Eliasof, Douglas Lazarus, Christian G. Peters, Roy I. Case, Roderic O. Cole, Jungyeon Hwang, Thomas Schluep, Joseph Chao, James Lin, Yun Yen, Han Han, Devin T. Wiley, Jonathan E. Zuckerman, Mark E. Davis

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Nanoparticles are currently being investigated in a number of human clinical trials. As information on how nanoparticles function in humans is difficult to obtain, animal studies that can be correlative to human behavior are needed to provide guidance for human clinical trials. Here, we report correlative studies on animals and humans for CRLX101, a 20- to 30-nm-diameter, multifunctional, polymeric nanoparticle containing camptothecin (CPT). CRLX101 is currently in phase 2 clinical trials, and human data from several of the clinical investigations are compared with results from multispecies animal studies. The pharmacokinetics of polymer-conjugated CPT (indicative of the CRLX101 nanoparticles) in mice, rats, dogs, and humans reveal that the area under the curve scales linearly with milligrams of CPT per square meter for all species. Plasma concentrations of unconjugated CPT released from CRLX101 in animals and humans are consistentwith each other after accounting for differences in serum albumin binding of CPT. Urinary excretion of polymer-conjugated CPT occurs primarily within the initial 24 h after dosing in animals and humans. The urinary excretion dynamics of polymer-conjugated and unconjugated CPT appear similar between animals and humans. CRLX101 accumulates into solid tumors and releases CPT over a period of several days to give inhibition of its target in animal xenograft models of cancer and in the tumors of humans. Taken in total, the evidence provided from animal models on the CRLX101 mechanism of action suggests that the behavior of CRLX101 in animals is translatable to humans.

Original languageEnglish
Pages (from-to)15127-15132
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number37
DOIs
Publication statusPublished - Sep 10 2013
Externally publishedYes

Fingerprint

Nanoparticles
Camptothecin
Clinical Trials
Polymers
Animal Models
Neoplasms
IT-101
Heterografts
Serum Albumin
Area Under Curve
Pharmacokinetics
Dogs

Keywords

  • Clinical translation
  • Interspecies scaling
  • Nanomedicine
  • Nanoparticles
  • Pharmacodynamics

ASJC Scopus subject areas

  • General

Cite this

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. / Eliasof, Scott; Lazarus, Douglas; Peters, Christian G.; Case, Roy I.; Cole, Roderic O.; Hwang, Jungyeon; Schluep, Thomas; Chao, Joseph; Lin, James; Yen, Yun; Han, Han; Wiley, Devin T.; Zuckerman, Jonathan E.; Davis, Mark E.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 37, 10.09.2013, p. 15127-15132.

Research output: Contribution to journalArticle

Eliasof, S, Lazarus, D, Peters, CG, Case, RI, Cole, RO, Hwang, J, Schluep, T, Chao, J, Lin, J, Yen, Y, Han, H, Wiley, DT, Zuckerman, JE & Davis, ME 2013, 'Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle', Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 37, pp. 15127-15132. https://doi.org/10.1073/pnas.1309566110
Eliasof, Scott ; Lazarus, Douglas ; Peters, Christian G. ; Case, Roy I. ; Cole, Roderic O. ; Hwang, Jungyeon ; Schluep, Thomas ; Chao, Joseph ; Lin, James ; Yen, Yun ; Han, Han ; Wiley, Devin T. ; Zuckerman, Jonathan E. ; Davis, Mark E. / Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 37. pp. 15127-15132.
@article{97e288b070b541e19f8653ea3c593e39,
title = "Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle",
abstract = "Nanoparticles are currently being investigated in a number of human clinical trials. As information on how nanoparticles function in humans is difficult to obtain, animal studies that can be correlative to human behavior are needed to provide guidance for human clinical trials. Here, we report correlative studies on animals and humans for CRLX101, a 20- to 30-nm-diameter, multifunctional, polymeric nanoparticle containing camptothecin (CPT). CRLX101 is currently in phase 2 clinical trials, and human data from several of the clinical investigations are compared with results from multispecies animal studies. The pharmacokinetics of polymer-conjugated CPT (indicative of the CRLX101 nanoparticles) in mice, rats, dogs, and humans reveal that the area under the curve scales linearly with milligrams of CPT per square meter for all species. Plasma concentrations of unconjugated CPT released from CRLX101 in animals and humans are consistentwith each other after accounting for differences in serum albumin binding of CPT. Urinary excretion of polymer-conjugated CPT occurs primarily within the initial 24 h after dosing in animals and humans. The urinary excretion dynamics of polymer-conjugated and unconjugated CPT appear similar between animals and humans. CRLX101 accumulates into solid tumors and releases CPT over a period of several days to give inhibition of its target in animal xenograft models of cancer and in the tumors of humans. Taken in total, the evidence provided from animal models on the CRLX101 mechanism of action suggests that the behavior of CRLX101 in animals is translatable to humans.",
keywords = "Clinical translation, Interspecies scaling, Nanomedicine, Nanoparticles, Pharmacodynamics",
author = "Scott Eliasof and Douglas Lazarus and Peters, {Christian G.} and Case, {Roy I.} and Cole, {Roderic O.} and Jungyeon Hwang and Thomas Schluep and Joseph Chao and James Lin and Yun Yen and Han Han and Wiley, {Devin T.} and Zuckerman, {Jonathan E.} and Davis, {Mark E.}",
year = "2013",
month = "9",
day = "10",
doi = "10.1073/pnas.1309566110",
language = "English",
volume = "110",
pages = "15127--15132",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "37",

}

TY - JOUR

T1 - Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

AU - Eliasof, Scott

AU - Lazarus, Douglas

AU - Peters, Christian G.

AU - Case, Roy I.

AU - Cole, Roderic O.

AU - Hwang, Jungyeon

AU - Schluep, Thomas

AU - Chao, Joseph

AU - Lin, James

AU - Yen, Yun

AU - Han, Han

AU - Wiley, Devin T.

AU - Zuckerman, Jonathan E.

AU - Davis, Mark E.

PY - 2013/9/10

Y1 - 2013/9/10

N2 - Nanoparticles are currently being investigated in a number of human clinical trials. As information on how nanoparticles function in humans is difficult to obtain, animal studies that can be correlative to human behavior are needed to provide guidance for human clinical trials. Here, we report correlative studies on animals and humans for CRLX101, a 20- to 30-nm-diameter, multifunctional, polymeric nanoparticle containing camptothecin (CPT). CRLX101 is currently in phase 2 clinical trials, and human data from several of the clinical investigations are compared with results from multispecies animal studies. The pharmacokinetics of polymer-conjugated CPT (indicative of the CRLX101 nanoparticles) in mice, rats, dogs, and humans reveal that the area under the curve scales linearly with milligrams of CPT per square meter for all species. Plasma concentrations of unconjugated CPT released from CRLX101 in animals and humans are consistentwith each other after accounting for differences in serum albumin binding of CPT. Urinary excretion of polymer-conjugated CPT occurs primarily within the initial 24 h after dosing in animals and humans. The urinary excretion dynamics of polymer-conjugated and unconjugated CPT appear similar between animals and humans. CRLX101 accumulates into solid tumors and releases CPT over a period of several days to give inhibition of its target in animal xenograft models of cancer and in the tumors of humans. Taken in total, the evidence provided from animal models on the CRLX101 mechanism of action suggests that the behavior of CRLX101 in animals is translatable to humans.

AB - Nanoparticles are currently being investigated in a number of human clinical trials. As information on how nanoparticles function in humans is difficult to obtain, animal studies that can be correlative to human behavior are needed to provide guidance for human clinical trials. Here, we report correlative studies on animals and humans for CRLX101, a 20- to 30-nm-diameter, multifunctional, polymeric nanoparticle containing camptothecin (CPT). CRLX101 is currently in phase 2 clinical trials, and human data from several of the clinical investigations are compared with results from multispecies animal studies. The pharmacokinetics of polymer-conjugated CPT (indicative of the CRLX101 nanoparticles) in mice, rats, dogs, and humans reveal that the area under the curve scales linearly with milligrams of CPT per square meter for all species. Plasma concentrations of unconjugated CPT released from CRLX101 in animals and humans are consistentwith each other after accounting for differences in serum albumin binding of CPT. Urinary excretion of polymer-conjugated CPT occurs primarily within the initial 24 h after dosing in animals and humans. The urinary excretion dynamics of polymer-conjugated and unconjugated CPT appear similar between animals and humans. CRLX101 accumulates into solid tumors and releases CPT over a period of several days to give inhibition of its target in animal xenograft models of cancer and in the tumors of humans. Taken in total, the evidence provided from animal models on the CRLX101 mechanism of action suggests that the behavior of CRLX101 in animals is translatable to humans.

KW - Clinical translation

KW - Interspecies scaling

KW - Nanomedicine

KW - Nanoparticles

KW - Pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=84883789058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883789058&partnerID=8YFLogxK

U2 - 10.1073/pnas.1309566110

DO - 10.1073/pnas.1309566110

M3 - Article

C2 - 23980155

AN - SCOPUS:84883789058

VL - 110

SP - 15127

EP - 15132

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 37

ER -